The HILOPRO® technology uses patented platform technology with GRAS excipients to enable innovator mAbs and biosimilars for SubQ delivery, optimized dosing, and enhanced market acceptance.
This single formulation technology works for a wide range of monoclonal antibodies, supports multiple dosing and delivery options, providing greater flexibility and optimal patient convenience.
High concentration, low viscosity, and low volume dosing open entirely new delivery possibilities.
HILOPRO® Tech enables biotherapeutics companies to expand their market share and maximize value creation through product life extension.
Our safe technology comes with benefits that no other innovation has been able to deliver.
Reduce cost by enabling at-home administration, minimal hospital visits, and enhancing the quality of life.
Uses GRAS excipients without adverse side effects or toxicity.
Less licensing fees compared to Halozyme’s ENHANZE® Technology.
Technology is validated by four major players in the biopharma industry
Our technology comprises two GRAS (Generally Regarded As Safe) category excipients approved by the US FDA.
Hilopro is a patent protected technology filed in 6 jurisdictions; a patent approved in the US jurisdiction.
BRL's High Concentration Protein Formulation Technology with its GRAS excipients outperformed all other published buffer and excipient combinations, resulting in high concentration formulations with significantly lower viscosity.
High concentration, low viscosity, and low-volume dosing open entirely new delivery possibilities. HILOPRO® Tech enables biotherapeutics companies to expand their market share and maximize value creation through product life extension.
Disclaimer: All trademarks, logos, and brand names are the property of their respective owners. All company, product, and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.
